NHS in England 均衡を保った to 配達する boosters
ワクチン接種 clinics have been given orders to be ready to start 配達するing boosters jabs “as soon as possible”.
NHS 長，指導者s in England have sent a letter to all 地元の health organisations 供給するing 指示／教授／教育s for an 切迫した start to the booster （選挙などの）運動をする.
It is 推定する／予想するd that the 国家の Bookings System will open on Monday to some people as they become 適格の for the jab.
People will be called 今後 to 調書をとる／予約する six months after they had their second dose.
Most ワクチン接種 clinics will begin the booster programme next week but a small number of 場所／位置s, 含むing some hospitals, could begin sooner.
And care home 居住（者）s should 推定する／予想する to get their booster by the end of next month.
The letter 明言する／公表するs that ワクチン接種 of health and social care 労働者s “can begin すぐに” in some hospitals.
The 共同の 委員会 on ワクチン接種 and Immunisation (JCVI) 始める，決める out its 計画（する） for boosters for more than 30 million B ritish adults on Tuesday.
The JCVI 表明するd a preference for people to get the Pfizer jab as a third dose, 関わりなく which jab they were 最初 given.
But it said that half doses of the Moderna jab could be used as an 代案／選択肢.
The letter, from Professor Sir Keith Willett and Dr Nikita Kinnari from NHS England, 明言する／公表するs people will be 申し込む／申し出d the Pfizer/BioNTech ワクチン, and 最初 the Moderna ワクチン will not be used in the programme, but it could be at a later date.
On the co-行政 of the flu jab, health leaders said that this should be considered “wherever 適格（性） for both programmes, 供給（する） and 規則 許す”.
But the NHS has been keen to 強調する／ストレス that people should not 延期する one ワクチン ーするために get both jabs at the same time.
GPs have also been ordered to 申し込む／申し出 the jab to care home 居住（者）s before November 1.
“場所／位置s should make 準備s to start vaccinating as soon as possible,” the letter 明言する／公表するs.
“It is 推定する／予想するd that we will open the 国家の 調書をとる／予約するing System for bookings and 問題／発行する first 国家の 招待s on Monday September 20.”
The letter 追加するs: “ワクチン接種 of health and social care 労働者s can begin すぐに in Hospital 中心s.
“This should be co-治めるd with flu ワクチン wherever possible.”
It 明言する／公表するs that the 国家の 調書をとる／予約するing system will be “open to people when they become 適格の, six months after their second jab, with 優先 for “those who are most at 危険 and those with the longest interval since the second dose of their 最初の／主要な course”.
On the ワクチン to be used it 明言する／公表するs: “We do not 推定する／予想する to go live with Moderna half doses すぐに.
“場所／位置s should not 治める half dose Moderna boosters until 教えるd to do so.
“In the 合間, systems should begin 治めるing booster ワクチン接種s with Pfizer.”
The news come as an 暫定的な 分析 on the safety and efficacy of Moderna booster doses was published in the 定期刊行物 Nature.
A small 熟考する／考慮する 診察するd a number of people 申し込む／申し出d a third dose of the ワクチン and variant tweaked booster as part of a 段階 two 裁判，公判.
Around 80 関係者s took part and showed elevated levels of antibodies after a booster.
Commenting on the 熟考する／考慮する, Jonathan Ball, professor of molecular virology at the University of Nottingham, said: “This 確認するs that an 付加 上げる of an mRNA ワクチン, in this 事例／患者 a high or lower dose of the Moderna ワクチン, 増加するs the level of ウイルス-殺人，大当り antibodies in the 血, 特に those able to kill variants of 関心.
“This is true irrespective of whether the ワクチン spike protein sequence is matched to the 初めの 緊張する of ウイルス or the Beta variant.
“Whilst the 熟考する／考慮する stopped short of showing whether it 増加するd 保護 against 感染 or 病気, it would be reasonable to assume that the higher antibody levels would be 有益な.
“This is one more piece of growing 証拠 to show that the 決定／判定勝ち（する） to give boosters to our most 攻撃を受けやすい people over the coming weeks and months was a sensible one.”
一方／合間, the company behind the Moderna ワクチン said its own 分析 has shown a lower 危険 of 打開 感染 ? where someone gets the ウイルス even though they have been vaccinated ? in those who had their first dose more recently.
The US-based 会社／堅い said 関係者s in the open-label 部分 of its 段階 three 熟考する／考慮する who had their first jab on 普通の／平均（する） eight months 以前 were at lower 危険 of 契約ing coronavirus than those who had their 初期の jab 13 months 以前.
Moderna, which said its 熟考する／考慮する will be submitted for peer-reviewed 出版（物）, said its data 論証するs the 衝撃 of 病弱なing 免疫 and 追加するs to 証拠 of the 可能性のある 利益 of a booster dose.
